Study of Belimumab in Patients with Systemic Lupus Erythematosus
Author Information
Author(s): Richard Furie, William Stohl, Ellen M Ginzler, Michael Becker, Nilamadhab Mishra, Winn Chatham, Joan T Merrill, Arthur Weinstein, W Joseph McCune, John Zhong, Wendy Cai, William Freimuth, the Belimumab Study Group
Hypothesis
Belimumab will demonstrate safety and biologic activity in patients with systemic lupus erythematosus.
Conclusion
Belimumab was well tolerated and reduced peripheral B-cell levels in SLE patients.
Supporting Evidence
- Belimumab reduced CD20+ B cells significantly compared to placebo.
- Adverse events were similar between belimumab and placebo groups.
- Pharmacokinetics of belimumab were linear across the tested dose range.
Takeaway
This study tested a new medicine called belimumab to see if it helps people with lupus by lowering certain bad cells in their blood.
Methodology
A phase I, double-blind, randomized study with 70 patients treated with either belimumab or placebo.
Potential Biases
Potential bias due to the small number of patients and the nature of the study design.
Limitations
The study had a small sample size and a short duration, which may limit the generalizability of the findings.
Participant Demographics
91% female, median age 38.5 years, diverse racial background with 50% white and 47% African American.
Statistical Information
P-Value
0.0042, 0.0036, 0.0305
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website